Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Seres Therapeutics (MCRB) over the last 6 years, with Q3 2025 value amounting to $351000.0.

  • Seres Therapeutics' Change in Receivables rose 10188.7% to $351000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $351000.0, marking a year-over-year increase of 10208.22%. This contributed to the annual value of -$8.7 million for FY2024, which is 20000.0% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Change in Receivables is $351000.0, which was up 10188.7% from -$18.6 million recorded in Q3 2024.
  • In the past 5 years, Seres Therapeutics' Change in Receivables registered a high of $11.2 million during Q2 2024, and its lowest value of -$18.6 million during Q3 2024.
  • For the 4-year period, Seres Therapeutics' Change in Receivables averaged around -$821454.5, with its median value being -$1.2 million (2021).
  • In the last 5 years, Seres Therapeutics' Change in Receivables crashed by 296202.53% in 2021 and then surged by 10188.7% in 2025.
  • Over the past 4 years, Seres Therapeutics' Change in Receivables (Quarter) stood at -$1.2 million in 2021, then crashed by 554.64% to -$8.2 million in 2023, then crashed by 127.31% to -$18.6 million in 2024, then skyrocketed by 101.89% to $351000.0 in 2025.
  • Its Change in Receivables was $351000.0 in Q3 2025, compared to -$18.6 million in Q3 2024 and $11.2 million in Q2 2024.